ALX Oncology Announces Upcoming Investor Conference Participation

Rhea-AI Summary

ALX Oncology Holdings Inc. (Nasdaq: ALXO), a clinical-stage immuno-oncology company, announced participation in two investor conferences. The first is Citi's 17th Annual BioPharma Conference on September 7 in Boston, MA. The second event is the H.C. Wainwright 24th Annual Global Investment Conference on September 12, featuring a fireside chat with analyst Swayampakula Ramakanth at 7:00 AM Eastern Time, available virtually. ALX is focused on developing therapies that target the CD47 checkpoint pathway, with promising results for its lead candidate, evorpacept.

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that management will participate in two upcoming investor conferences.

Citi's 17th Annual BioPharma Conference
Format: Investor meetings
Date: Wednesday, September 7
Location: Boston, MA

H.C. Wainwright 24th Annual Global Investment Conference
Format: Fireside chat with analyst, Swayampakula Ramakanth
Date: Monday, September 12
Time: 7:00 AM Eastern Time
Location: Virtual
Webcast link: Available here

A live webcast of the H.C. Wainwright fireside chat is available here and can be accessed by visiting the Investors section of ALX Oncology’s website at www.alxoncology.com and selecting Events under the News and Events tab. A replay of the webcast will be archived for up to 90 days following the fireside chat date.

About ALX Oncology

ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology’s lead product candidate, evorpacept, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. Evorpacept has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents. ALX Oncology intends to continue clinical development of evorpacept for the treatment of multiple solid tumor indications and hematologic malignancies.

Investor Contact:

Peter Garcia
Chief Financial Officer, ALX Oncology
(650) 466-7125 Ext. 113
peter@alxoncology.com

Argot Partners
(212) 600-1902
alxoncology@argotpartners.com

Media Contact:

Karen Sharma
MacDougall
(781) 235-3060
alx@macbiocom.com

FAQ

What is ALX Oncology's participation in the upcoming investor conferences?

ALX Oncology will participate in Citi's 17th Annual BioPharma Conference on September 7 and the H.C. Wainwright 24th Annual Global Investment Conference on September 12.

When and where is the H.C. Wainwright conference taking place?

The H.C. Wainwright 24th Annual Global Investment Conference is on September 12 at 7:00 AM Eastern Time, held virtually.

What is the focus of ALX Oncology's research?

ALX Oncology is focused on developing therapies that block the CD47 checkpoint pathway to treat cancer.

What is ALX Oncology's leading product candidate?

ALX Oncology's leading product candidate is evorpacept, which targets the CD47 pathway.

How can investors access the H.C. Wainwright fireside chat?

Investors can access the H.C. Wainwright fireside chat virtually through a webcast link available on ALX Oncology’s website.